Adding Blinatumomab to Chemotherapy Improves DFS in Patients with Newly Diagnosed Childhood Standard-Risk B-Cell ALL of Average or High Risk of Relapse By Ogkologos - January 13, 2025 864 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the COG AALL1731 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Joins WHO Global Clinical Trials Forum to Strengthen Global Oncology Research Ecosystems EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom Responses Over Ruxolitinib in Patients with JAK Inhibitor-Naïve Myelofibrosis MOST POPULAR Can we grow the treatments of tomorrow? – That Cancer Conversation September 2, 2021 Blinatumomab Increases Survival for Infants with an Aggressive Type of ALL June 8, 2023 Women in science: Cancer research pioneers – part 1 January 18, 2023 Telehealth Can Save People with Cancer Time, Travel, and Money February 16, 2023 Load more HOT NEWS Breast Cancer Patient Devotes Her Time to Driving Others to Treatment ScottishPower supports vital research into air pollution and cancer Analysis Patterns of Systemic Anticancer Treatment at End-of-Life Indicates No Changes... Immunotherapy Combinations for Treating Metastatic Melanoma and Using Technology to Find...
